GlaxoSmithKline

Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety...

prnewswire.com     4 hrs ago   3 related          

Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced...                    

comments

Stockwire.com: (OTCBB:UGNE) Unigene Laboratories, Inc. just released some important news.

tmcnet.com     7 hrs ago   3 related          

OTCBB:UGNE) Unigene Laboratories, Inc. - Unigene to Release Second Quarter Financial Results and Host Conference Call A dedicated Chat Room for (OTCBB:UGNE) Unigene Laboratories, Inc., has been created at STOCKWIRE.com to...                    

comments

                   

XenoPort shares fall on wider-than-expected loss

ibtimes.com     5 hrs ago   1 related          

SANTA CLARA, Calif. - Shares of biotechnology company XenoPort Inc. fell Thursday after the company reported a wider-than-expected second-quarter loss on dwindling revenue from drug development deals. The stock fell $1.21, or...                    

comments

                   

The Next Pharma Acquisition (at Motley Fool)

yahoo.com     3 hrs ago   1 related          

The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, but I can't see it slowing down anytime soon. If a company has multiple partnerships, like Biogen Idec (Nasdaq: BIIB), the joint ventures...                    

comments

                   

CMG Holdings, Inc., Creative Management Group Inc. (CMGO) to Acquire Maya Marketing, Inc....

yahoo.com     4 hrs ago          

NEW YORK----CMG Holdings, Inc. , a full service global marketing, sports, entertainment and management communications company that operates in the sectors of talent management, event management and commercial rights, has...                    

comments

                   

Isis Reports Financial Results and Highlights for Second Quarter of 2008

prnewswire.com     10 hrs ago   5 related          

today announced its financial results for the second quarter ended June 30, 2008. Potential acquisition of Ibis by Abbott Financial Results Isis had $873,000 of pro forma profit from operations in the second quarter of 2008 and...                    

comments

Troux Directions Europe 2008 Rapidly Approaching Event Capacity

searchbyheadlines.com     11 hrs ago          

Global demand for Strategic IT Planning solutions credited for driving record pre-event registration Austin, TX and London, UK -- Troux Technologies, the acknowledged market leader in Strategic IT Planning, today announced that...                    

comments

                   

Analysis of Six Clinical Trials Finds EPZICOM(R) Effective in Treatment-Naive HIV Patients With...

yahoo.com     3 hrs ago          

Thursday August 7, 2:30 pm ET MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- News ) announced that a retrospective analysis of six clinical trials found that anti-HIV regimens containing EPZICOM (abacavir + lamivudine) were...                    

comments

                   

Synta Pharmaceuticals Reports Second Quarter 2008 Financial Results

earthtimes.org     10 hrs ago          

LEXINGTON, Mass. - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported...                    

comments

                   

Tolerx Initiates Dosing Of Otelixizumab, A Novel Type 1 Diabetes Agent, In DEFEND, A Phase 3...

medicalnewstoday.com     12 hrs ago   3 related          

Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, announced the initiation of a pivotal Phase 3 clinical trial that is evaluating otelixizumab in...                    

comments

1 2 3 4 5 next »